Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 8,612 matching trials from the live ClinicalTrials.gov search.

Filters: Indianapolis, Indiana Clear all

Conditions: Rheumatoid Arthritis
Interventions: Micellar Paclitaxel for Injection; Drug
Lead sponsor: Angiotech Pharmaceuticals; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 9
States / cities: Birmingham, Alabama • Denver, Colorado • Daytona Beach, Florida + 6 more

Conditions: Anesthesia, Pediatrics, Surgery
Interventions: regional nerve block, Antiemetic; Procedure · Drug
Lead sponsor: Indiana University; Other
Eligibility: 1 Year to 18 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Rheumatoid Arthritis
Interventions: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB), Infliximab (INF) + MTX, DB, Placebo (PLA) + MTX, DB, PLA + MTX switched to ABA+ MTX, DB, ABA, open-label (OL); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 19
States / cities: Huntsville, Alabama • Denver, Colorado • Boca Raton, Florida + 16 more

Conditions: Nausea, Vomiting
Interventions: Enterra Therapy System; Device
Lead sponsor: Enterra Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 12
States / cities: Scottsdale, Arizona • Los Angeles, California • Newport Beach, California + 9 more

Conditions: Sepsis, Adult Disease, Severe Sepsis, Emergency Department
Interventions: CBC-DIFF Monocyte Volume Width Distribution (MDW); Diagnostic Test
Lead sponsor: Beckman Coulter, Inc.; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pleuropulmonary Blastoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Recurrent Synovial Sarcoma, Wilms Tumor
Interventions: Laboratory Biomarker Analysis, Lorvotuzumab Mertansine, Pharmacological Study; Other · Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Months to 30 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 69
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more

Conditions: Germ Cell Tumor, Testis Cancer, Testicular Cancer
Interventions: Guadecitabine (SGI-110); Drug
Lead sponsor: Nasser Hanna; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: B-cell Lymphoma
Interventions: Parsaclisib, Rituximab, Bendamustine, Ibrutinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 9
States / cities: Tucson, Arizona • Indianapolis, Indiana • Las Vegas, Nevada + 4 more

Conditions: Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma of the Lung, Lung Cancer, Squamous Cell Lung Cancer
Interventions: Docetaxel, Nivolumab, Gemcitabine, Pemetrexed; Drug
Lead sponsor: Nasser Hanna, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 9
States / cities: Anderson, Indiana • Indianapolis, Indiana • Muncie, Indiana + 4 more

Conditions: Migraine
Interventions: AMG 334 Dose 1, AMG 334 Dose 2, AMG 334 Dose 3; Drug
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 14
States / cities: Little Rock, Arkansas • Englewood, Colorado • Stamford, Connecticut + 11 more

Conditions: Advanced Squamous Non-Small Cell Lung Cancer
Interventions: AMG 479, Carboplatin, Paclitaxel; Biological · Drug
Lead sponsor: NantCell, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 25
States / cities: Fayetteville, Arkansas • Fort Wayne, Indiana • Indianapolis, Indiana + 9 more

Conditions: Intrauterine Devices
Interventions: Intrauterine device; Device
Lead sponsor: Bayer; Industry
Eligibility: Up to 50 Years · Female only
Enrollment: 326,658 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Oakland, California • Pasadena, California • Indianapolis, Indiana + 1 more

Conditions: Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Neoplasm, Primary Peritoneal Carcinoma
Interventions: Evaluation of Cancer Risk Factors, Quality-of-Life Assessment, Questionnaire Administration, Study of High Risk Factors; Procedure · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 30 Years and older · Female only
Enrollment: 1,916 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 141
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 106 more

Conditions: Dementia, Alzheimer's Disease
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 55 Years to 95 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 14
States / cities: Santa Ana, California • Hamden, Connecticut • Hialeah, Florida + 11 more

Conditions: Neoplasms, Breast
Interventions: pazopanib (GW786034) 400 mg, lapatinib (GW572016) 1500 mg, lapatinib (GW572016) 1000 mg, pazopanib (GW786034) 800 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 19
States / cities: Jonesboro, Arkansas • Alhambra, California • Bakersfield, California + 16 more

Conditions: Wounds, Wounds and Injuries, Extremity Injury, Traumatic Wounds and Injuries, Amputation, Traumatic/Surgery, Amputation, Wound, Open Fracture Wounds
Interventions: Clinical Decision Support Tool, Standard of Care (SOC); Device · Procedure
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 5
States / cities: Birmingham, Alabama • Atlanta, Georgia • Indianapolis, Indiana + 2 more

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: Obeticholic Acid (OCA), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 33
States / cities: Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 23 more

Conditions: Chronic Kidney Disease
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 25
States / cities: Birmingham, Alabama • Palo Alto, California • Sacramento, California + 22 more

Conditions: HIV
Interventions: Efavirenz; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Liver Diseases
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: 24 Hours to 25 Years
Enrollment: 171 participants
Timeline: 2022 – 2026
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With, Glucocorticoid-induced Osteoporosis
Interventions: Denosumab, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 6
States / cities: Los Angeles, California • Wilmington, Delaware • Indianapolis, Indiana + 3 more

Conditions: Cancer
Interventions: Montreal Cognitive Assessment (MoCA); Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Exudative Age-related Macular Degeneration
Interventions: 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea, sham injection; Drug
Lead sponsor: Lpath, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 44
States / cities: Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer With Bone Involvement, Bone Metastases in Subjects With Advanced Breast Cancer, ER-Positive HER2-Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Hormone-sensitive Metastatic Breast Cancer, Hormone-Sensitive Breast Cancer
Interventions: RYZ101, Standard of Care Endocrine Therapy; Drug
Lead sponsor: RayzeBio, Inc.; Industry
Eligibility: Not listed
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 25
States / cities: Phoenix, Arizona • Irvine, California • San Diego, California + 21 more

Search by objective public record fields.

A Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis

Comparative Study of Superficial Cervical Plexus Block and Nerve of Arnold Block and Incidence of PONV for Inner Ear Surgery

Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis

Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)

Sepsis Post Market Clinical Utility Simple Endpoint Study - Indiana University Hospital

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

AMG 334 20160172 Pediatric Migraine PK Study.

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Study on Medical Records of Women Using an Intrauterine Device (IUD) to Analyze the Risks That the IUD Will be Expelled or Perforates the Womb in Relation to Breastfeeding, the Point in Time When the IUD Was Inserted After Childbirth and in Relation to Different Types of IUDs

Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

Pilot Trial for WounDx™ Clinical Decision Support Tool

Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics

Genetic Collection Protocol

Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis

Serial Testing To Assess Cognitive Function In Cancer

Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.